Format

Send to

Choose Destination
Dermatology. 2009;219(2):148-54. doi: 10.1159/000228334. Epub 2009 Jul 8.

Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.

Author information

1
Service de Dermatologie, Groupe Henri-Mondor Albert-Chenevier, AP-HP, Créteil, France.

Abstract

BACKGROUND:

Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available.

OBJECTIVE:

To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS.

METHODS:

Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment.

RESULTS:

The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects.

CONCLUSION:

The combination of clindamycin and rifampicin is effective in the treatment of severe HS.

PMID:
19590173
DOI:
10.1159/000228334
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center